Hence, in this review, we will focus on age-dependent differences in the previously described mechanisms of resistance to PD1/PDL1 inhibitors (Figure 1) and discuss the development of potential combination treatment strategies for enhancing the anti-tumor efficacy of anti-PD1/PDL1 treatment in younger melanoma patients. This evidence concerns the gene CD274 and melanoma.